RLMD Stock Catalyst: Relmada Therapeutics Acquires Sepranolone from Asarina Pharma

Feb 5, 2025 · 7:58pm ET

The acquisition includes a Phase 2b ready neurosteroid.

Max move

+56.8%

High of day $0.58

Sparker timei

7:58pm ET

RLMD · Feb 5, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Relmada Therapeutics, Inc. (XNAS: RLMD) announced on February 6, 2025, the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB. Sepranolone is intended for the treatment of Tourette syndrome and other compulsive disorders.

The transaction value was EUR 3 million. Relmada Therapeutics now holds the rights to develop and commercialize Sepranolone.

Relmada Therapeutics has a free float of 65,450,000 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time RLMD sparks.

Download Sniper App →

Catch the next RLMD-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →